Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma

被引：23

作者：

Tang, Linsong ^{[1
,2
]}

Chen, Ronggao ^{[1
,2
]}

Xu, Xiao ^{[1
,2
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Dept Surg,Sch Med, Hangzhou 310003, Peoples R China

[2] Minist Publ Hlth, NHFPC Key Lab Combined Multiorgan Transplantat, Hangzhou 310003, Peoples R China

来源：

CANCER LETTERS | 2020年 / 476卷

基金：

国家杰出青年科学基金;

关键词：

Hepatocellular carcinoma; Synthetic lethality; Screening technology; Genetic interactions; SENSITIZES CANCER-CELLS; ATR-INHIBITION; BETA-CATENIN; MYC; SCREEN; SORAFENIB; P53; VULNERABILITY; KINASE; TUMORS;

D O I：

10.1016/j.canlet.2020.02.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC), the main cause of liver cancer-related death, is one of the main cancers in terms of incidence and mortality. However, HCC is difficult to target and develops strong drug resistance. Therefore, a new treatment strategy is urgently needed. The clinical application of the concept of synthetic lethality in recent years provides a new therapeutic direction for the accurate treatment of HCC. Here, we introduce the concept of synthetic lethality, the screening used to study synthetic lethality, and the identified and potential genetic interactions that induce synthetic lethality in HCC. In addition, we propose opportunities and challenges for translating synthetic lethal interactions to the clinical treatment of HCC.

引用

页码：120 / 128

页数：9

共 114 条

[1] A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease [J].

Abul-Husn, N. S. ;

Cheng, X. ;

Li, A. H. ;

Xin, Y. ;

Schurmann, C. ;

Stevis, P. ;

Liu, Y. ;

Kozlitina, J. ;

Stender, S. ;

Wood, G. C. ;

Stepanchick, A. N. ;

Still, M. D. ;

McCarthy, S. ;

O'Dushlaine, C. ;

Packer, J. S. ;

Balasubramanian, S. ;

Gosalia, N. ;

Esopi, D. ;

Kim, S. Y. ;

Mukherjee, S. ;

Lopez, A. E. ;

Fuller, E. D. ;

Penn, J. ;

Chu, X. ;

Luo, J. Z. ;

Mirshahi, U. L. ;

Carey, D. J. ;

Still, C. D. ;

Feldman, M. D. ;

Small, A. ;

Damrauer, S. M. ;

Rader, D. J. ;

Zambrowicz, B. ;

Olson, W. ;

Murphy, A. J. ;

Borecki, I. B. ;

Shuldiner, A. R. ;

Reid, J. G. ;

Overton, J. D. ;

Yancopoulos, G. D. ;

Hobbs, H. H. ;

Cohen, J. C. ;

Gottesman, O. ;

Teslovich, T. M. ;

Baras, A. ;

Mirshahi, T. ;

Gromada, J. ;

Dewey, F. E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12) :1096-1106

[2]

Anderson SC, 1998, CLIN CANCER RES, V4, P1649

[3]

[Anonymous], CLIN CANC RES

[4]

[Anonymous], J CLIN ONCOL

[5]

[Anonymous], BMC CANC

[6] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].

Audeh, M. William ;

Carmichael, James ;

Penson, Richard T. ;

Friedlander, Michael ;

Powell, Bethan ;

Bell-McGuinn, Katherine M. ;

Scott, Clare ;

Weitzel, Jeffrey N. ;

Oaknin, Ana ;

Loman, Niklas ;

Lu, Karen ;

Schmutzler, Rita K. ;

Matulonis, Ursula ;

Wickens, Mark ;

Tutt, Andrew .

LANCET, 2010, 376 (9737) :245-251

[7] PIN1 in hepatocellular carcinoma is associated with TP53 gene status [J].

Bae, Jun Sang ;

Noh, Sang Jae ;

Kim, Kyoung Min ;

Jang, Kyu Yun ;

Park, Ho Sung ;

Chung, Myoung Ja ;

Park, Byung-Hyun ;

Moon, Woo Sung .

ONCOLOGY REPORTS, 2016, 36 (04) :2405-2411

[8] Comprehensive molecular characterization of gastric adenocarcinoma [J].

Bass, Adam J. ;

Thorsson, Vesteinn ;

Shmulevich, Ilya ;

Reynolds, Sheila M. ;

Miller, Michael ;

Bernard, Brady ;

Hinoue, Toshinori ;

Laird, Peter W. ;

Curtis, Christina ;

Shen, Hui ;

Weisenberger, Daniel J. ;

Schultz, Nikolaus ;

Shen, Ronglai ;

Weinhold, Nils ;

Keiser, David P. ;

Bowlby, Reanne ;

Sipahimalani, Payal ;

Cherniack, Andrew D. ;

Getz, Gad ;

Liu, Yingchun ;

Noble, Michael S. ;

Pedamallu, Chandra ;

Sougnez, Carrie ;

Taylor-Weiner, Amaro ;

Akbani, Rehan ;

Lee, Ju-Seog ;

Liu, Wenbin ;

Mills, Gordon B. ;

Yang, Da ;

Zhang, Wei ;

Pantazi, Angeliki ;

Parfenov, Michael ;

Gulley, Margaret ;

Piazuelo, M. Blanca ;

Schneider, Barbara G. ;

Kim, Jihun ;

Boussioutas, Alex ;

Sheth, Margi ;

Demchok, John A. ;

Rabkin, Charles S. ;

Willis, Joseph E. ;

Ng, Sam ;

Garman, Katherine ;

Beer, David G. ;

Pennathur, Arjun ;

Raphael, Benjamin J. ;

Wu, Hsin-Ta ;

Odze, Robert ;

Kim, Hark K. ;

Bowen, Jay .

NATURE, 2014, 513 (7517) :202-209

[9] Synthetic Lethality in Cancer Therapeutics [J].

Beijersbergen, Roderick L. ;

Wessels, Lodewyk F. A. ;

Bernards, Rene .

ANNUAL REVIEW OF CANCER BIOLOGY, VOL 1, 2017, 1 :141-161

[10] Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers [J].

Bitler, Benjamin G. ;

Aird, Katherine M. ;

Garipov, Azat ;

Li, Hua ;

Amatangelo, Michael ;

Kossenkov, Andrew V. ;

Schultz, David C. ;

Liu, Qin ;

Shih, Ie-Ming ;

Conejo-Garcia, Jose R. ;

Speicher, David W. ;

Zhang, Rugang .

NATURE MEDICINE, 2015, 21 (03) :231-+

← 1 2 3 4 5 6 7 8 9 10 →